Please login to the form below

Not currently logged in
Email:
Password:

Boehringer, Lilly get EU approval for diabetes combo Jentadueto

Continues the advance of pharma companies’ collaboration

Eli Lilly and Boehringer Ingelheim have secured marketing approval for their fixed-dose combination drug Jentadueto for type 2 diabetes in the EU and have said it will be available across Europe soon.

Jentadueto combines the DPP-4 inhibitor linagliptin, which Boehringer and Lilly market as Trajenta in Europe (and as Tradjenta in the US), with the older generic drug metformin.

The new drug is an important line extension for Trajenta, which was approved a year ago in Europe to treat type 2 diabetes alongside metformin and sulphonylurea drugs. The fixed dose combination means that people with diabetes can take just one tablet twice a day to help control blood sugar.

Specifically, the European Commission approved Jentadueto for use alongside diet and exercise to improve glycaemic control in adults with type 2 diabetes who are inadequately controlled on their maximal tolerated dose of metformin alone, metformin and a sulphonylurea, or those already being treated with the combination of Trajenta and metformin given as separate doses, said Boehringer.

Jentadueto was cleared by the US Food and Drug Administration (FDA) earlier this year and the line extension is considered critical if Boehringer and Lilly's linagliptin franchise is to compete with the current crop of DPP-4 inhibitors, currently led by Merck & Co's Januvia (sitagliptin) and Janumet (sitagliptin and metformin).

Januvia/Janumet pulled in $4.7bn in sales last year for Merck and has got off to a strong start on 2012, with first quarter sales up more than 40 per cent year-on-year.

Meanwhile, Jentadueto is going up against two other DPP-4 inhibitors - Bristol-Myers/AstraZeneca's Onglyza (saxagliptin), and Novartis' Galvus (vildagliptin) - with 2011 sales of $684m and $677m in 2011.

Both saxagliptin and vildagliptin are already available in fixed-dose combinations with metformin, and Boehringer and Lilly are hoping that linagliptin's tolerability, along with no need for dose adjustment in patients with impaired liver or kidney function, will help drive uptake.

Lilly and Boehringer entered into an alliance on diabetes in January 2011 to co-develop and co-market four diabetes drugs, including linagliptin, Boehringer oral diabetes drug BI10773 and two of Lilly's basal insulin analogues, LY2605541 and LY2963016.

25th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

What pharma marketers can learn from growth hacking?
Growth hackers instinctively blend technical skills with creative thinking...
Medicines for Europe
The sound of silence puts the squeeze on generics and biosimilars
Medicines for Europe vows to get governments talking to realise potential...
03_analytical_lowres.jpg
How to choose your digital channels
Like many other areas of marketing, pharma digital communication is subject to fashion. A new technology arrives, people naturally get excited. Meanwhile, established communication technologies receive less focus (even if...

Infographics